Global Zellweger Spectrum Disorder Market Highlights Over 2022 – 2031
The global Zellweger spectrum disorder market is estimated to garner a CAGR of ~6% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to increased research activities regarding the Zellweger spectrum disorder. The National Center for Biotechnology Information stated that the Zellweger disorder is the result of a mutation in any of the 12 PEX genes and it is estimated to affect about 1 in 50,000 to 1 in 75,000 infants. Furthermore, the Zellweger spectrum disorder market is expected to prosper over the forecast period owing to a rise in screening tests and advanced diagnostic of the disease. Governments are working towards making people aware of rare diseases. It is estimated that around USD 998 billion is spent for treatment and awareness regarding rare diseases, out of which, USD 450 billion is the direct medical cost and the rest is the indirect and non-medical costs.
With the escalating awareness regarding Zellweger disorders, doctors and parents are becoming precautious regarding the occurrence of any rare disease, such as Zellweger disorder. Furthermore, the syndrome has no cure but the therapies may ease the symptoms. The ease of getting access to advanced diagnostic tools, natural history studies, and enhanced electronic health records is expected to escalate the global Zellweger spectrum disorder market during the forecast period.
Get more information on this report: Request Sample PDF
The market is segmented by end-user into hospitals, clinics, diagnostic centers, and genetic testing laboratories, out of which, the hospital segment is anticipated to hold the notable share in the global Zellweger spectrum disorder market on account of the highest flow of patients in the hospitals. As doctors are precautious and suggest tests for the parents owing to this the global Zellweger spectrum disorder market is expected to grow during the forecast period.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Zellweger Spectrum Disorder Market Regional Synopsis
Regionally, the global Zellweger spectrum disorder market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America region is estimated to witness noteworthy growth over the forecast period on the back of impeccable research and healthcare infrastructure. There is a provision for the screening test for newborn babies, which leads to the availability of highly developed diagnostic equipment. According to the data by the World Bank, North America spent 2.734% of its GDP for R&D activities in 2018. On account of this, the global Zellweger spectrum disorder is expected to grow in the region during the forecast period
The global Zellweger spectrum disorder market is expected to grow significantly in Europe region, on account of rising initiatives for the detection and treatment of the disorder. The doctors are more vigilant and render genetic counseling to the parents, which is why, the global Zellweger spectrum disorder market is projected to witness significant growth over the forecast period.
Get more information on this report: Request Sample PDF
The global Zellweger spectrum disorder market is further classified on the basis of region as follows:
-
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
-
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
-
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
-
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
-
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
Market Segmentation
Our in-depth analysis of the global Zellweger spectrum disorder market includes the following segments:
By Therapy
- Paediatricians
- Neurologists
- Surgeons
- Audiologist
- Ophthalmologists
- Orthopedists
By Diagnosis
- Blood & Urine Test
- Ultrasound
- Genetic Test
By End-User
- Hospitals
- Clinics
- Diagnostic Centres
- Genetic Testing Laboratories
Growth Drivers
- Growing Research for Zellweger Spectrum Disorder
- Increasing Awareness Regarding Rare Diseases
Challenges
- High Cost of Therapies
- Lack of Clinical Data
Top Featured Companies Dominating the Market
- Invitae Corporations.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CENTOGENE N.V.
- GeneDx, LLC
- Blueprint Genetics Oy
- Siemens Healthcare Gmbh
- Carestream Health, Inc.
- Agfa-Gevaert Group
- Shimadzu Corporation
- Asper Biogene LLC
- Trivitron Healthcare
